STAG. Sulcus Line of the Trochlear Alignment. - Orthopaedic prosthesis implantation instrument, reusable Australia - English - Department of Health (Therapeutic Goods Administration)

stag. sulcus line of the trochlear alignment. - orthopaedic prosthesis implantation instrument, reusable

framont holdings pty ltd -

IRINOTECAN ACT irinotecan hydrochloride trihydrate 500mg/25mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan act irinotecan hydrochloride trihydrate 500mg/25ml concentrated injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate -

IRINOTECAN ACT irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan act irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate -

IRINOTECAN ACT irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan act irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

medis pharma pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: (s)-lactic acid; water for injections; sodium hydroxide; sorbitol - for use as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum and in patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN ACCORD irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan accord irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: hydrochloric acid; lactic acid; sodium hydroxide; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN ACCORD irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan accord irinotecan hydrochloride trihydrate 40 mg/2 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

MEDITAB IRINOTECAN irinotecan hydrochloride trihydrate 40 mg / 2 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

meditab irinotecan irinotecan hydrochloride trihydrate 40 mg / 2 ml injection vial

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sodium hydroxide; water for injections; lactic acid; sorbitol - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

MEDITAB IRINOTECAN irinotecan hydrochloride trihydrate 100 mg / 5 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

meditab irinotecan irinotecan hydrochloride trihydrate 100 mg / 5 ml injection vial

cipla australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection - excipient ingredients: sorbitol; lactic acid; water for injections; sodium hydroxide - as a component of first line therapy for patients with metastatic carcinoma of the colon or rectum. patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN WKT irinotecan hydrochloride 40mg/2mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan wkt irinotecan hydrochloride 40mg/2ml injection vial

wockhardt bio pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: lactic acid; water for injections; hydrochloric acid; sorbitol; sodium hydroxide - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN WKT irinotecan hydrochloride 500mg/25mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

irinotecan wkt irinotecan hydrochloride 500mg/25ml injection vial

wockhardt bio pty ltd - irinotecan hydrochloride trihydrate, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: sorbitol; sodium hydroxide; hydrochloric acid; lactic acid; water for injections - irinotecan injection is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.